For a patient with metastatic colon cancer who tested positive for MSI (i.e. MLH1 hypermethylation etc) and BRAF mutation, what would be your preferred choice in the second line setting?  

Would you choose to use IO or BRAF directed therapy based on BEACON? Or would you continue to use cytotoxic chemotherapy?



Answer from: Medical Oncologist at Community Practice
Comments
Medical Oncologist at Texas Oncology-San Antonio Babcock
Do you consider MLH1/PMS2 hypermethylation MMR/def...
Medical Oncologist at Texas Oncology-San Antonio Babcock
Especially when they turn out to be BRAF Mutant?
Medical Oncologist at Indiana University Melvin and Bren Simon Cancer Center
Yes, those patients are considered MMR-D. 
Sign in or Register to read more

Answer from: Medical Oncologist at Academic Institution